TY - JOUR T1 - Sulodexide in the treatment of patients with early stages of COVID-19: a randomised controlled trial JF - medRxiv DO - 10.1101/2020.12.04.20242073 SP - 2020.12.04.20242073 AU - Alejandro J. Gonzalez-Ochoa AU - Joseph D. Raffetto AU - Ana G. Hernández AU - Nestor Zavala AU - Obed Gutiérrez AU - Arturo Vargas AU - Jorge Loustaunau Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20242073.abstract N2 - Background Targeting endothelial cells has been suggested for the treatment of patients with COVID-19 and sulodexide has pleiotropic properties within the vascular endothelium that can prove beneficial to the same. We aimed to evaluate the effect of sulodexide when used in the early clinical stages of COVID-19.Methods We conducted a single-centre, outpatient setting, randomised controlled trial with a parallel-group design in Mexico. Including patients within three days of clinical symptom onset, who were at a high risk of severe clinical progression due to chronic comorbidities. Participants were randomly allocated to receive an oral dose of sulodexide (500 LRU twice a day) or the placebo for 21 days. Primary outcomes were need and length of hospitalisation, need and length of oxygen support.Results Between June 5 and August 30, 2020, 243 patients were included in the “per-protocol” analysis. One hundred twenty-four of them received sulodexide, while 119 received placeboes. At 21 days follow-up, 22 of 124 patients required hospitalisation in the sulodexide group compared to 35 of 119 in the placebo group [relative risk (RR), 0·6; 95% confidence interval (CI), 0·37-0·96; p=0·03]. Fewer patients required oxygen support in the sulodexide group [37 of 124 vs. 50 of 119; RR, 0·71; 95% CI, 0·5 to 1; p=0·05], and for fewer days (9±7·2 in the sulodexide group vs. 11·5±9·6 in the placebo group; p=0·02). There was no between-group difference concerning the length of hospital stay.Interpretation Early intervention in COVID-19 patients with sulodexide reduced hospital admissions and oxygen support requirements, although with no significant effect on mortality. This has beneficial implications in the patient well-being, making sulodexide a favourable medication until an effective vaccine or an antiviral becomes available.Funding Researcher independently initiated, partially funded by Alfasigma, Mexico.Listed in the ISRCTN registry under ID ISRCTN59048638.Competing Interest StatementAGO has received speaker fees, honoraria, and travel reimbursement from Alfasigma Mexico for research outside of this submitted study. All other authors declare no competing interests.Clinical TrialISRCTN Registry ID ISRCTN59048638.Clinical Protocols https://www.isrctn.com/ISRCTN59048638?q=sulodexide&filters=&sort=&offset=1&totalResults=3&page=1&pageSize=10&searchType=basic-search Funding StatementThis study was independently initiated by the lead researcher and partially funded by Alfasigma Mexico, with the latter providing support for sulodexide and placebo capsules for the trial duration. Alfasigma did not contribute to trial enrolments; data collection, management, analysis and interpretation; or the decision to submit the report for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Universidad Autonoma de Baja California Faculty of Medicine Mexicali Ethics and Investigation Committee, designated approval number FMM/CEI/0011/2020-2.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed and presented in this study are available from the corresponding author on reasonable request, providing the request meets local ethical and research governance criteria. ER -